SCHEMBL3408570

SCHEMBL3408570

[HH].[HH].[NaH]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3963314 1.00
SCHEMBL11631041 1.00
SCHEMBL28173408 1.00
SCHEMBL7068760 1.00
SCHEMBL11633001 1.00
SCHEMBL10388761 1.00
SCHEMBL11629843 1.00
Fluoride SCHEMBL23065011 0.82
Iodide SCHEMBL2872084 0.82
SCHEMBL1361568 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570666-B2 Furoindazole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2026-03-10 US disclosed
EP-4077334-B1 FUROINDAZOLE DERIVATIVES BAYER AG (DE) 2025-03-12 EP disclosed
US-20230112499-A1 FUROINDAZOLE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
EP-4077334-A1 FUROINDAZOLE DERIVATIVES Bayer Aktiengesellschaft (DE) 2022-10-26 EP disclosed
WO-2021122415-A9 FUROINDAZOLE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2022-06-30 WO disclosed
US-20220089540-A1 COMPOSITIONS AND METHODS FOR IMMUNE MODULATION AND TREATMENT OF CANCER BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY 2022-03-24 US disclosed
EP-3911309-A1 COMPOSITIONS AND METHODS FOR IMMUNE MODULATION AND TREATMENT OF CANCER Board Of Trustees Of Michigan State University (US) 2021-11-24 EP disclosed
CN-113621001-A Organic electroluminescent material and device 环球展览公司 2021-11-09 CN disclosed
WO-2021122415-A1 FUROINDAZOLE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2021-06-24 WO disclosed
WO-2021033980-A1 NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME 주식회사 엘지화학 2021-02-25 WO disclosed
CN-104445793-B A kind of method of processing ethylene waste lye up to standard SINOPEC CORP. (CN) 2016-05-25 CN disclosed
CN-105593422-A Fire resistant panel and methods of fire blocking an article DREAMWELL LTD 2016-05-18 CN disclosed
CN-104194385-B A kind of azo group 1:2 premetallized dye composition and tint applications thereof SHANGHAI ARGUS TEXTILE CHEMICAL CO., LTD. (CN) 2016-05-11 CN disclosed
CN-103443933-B Backboard used for solar batteries and manufacture method thereof and solar module FUJIFILM CORP. (JP) 2016-05-04 CN disclosed
EP-2262795-A1 MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF AstraZeneca AB (SE) 2010-12-22 EP disclosed
WO-2009110844-A1 MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF ASTRAZENECA AB (SE) 2009-09-11 WO disclosed
US-20090221642-A1 MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF-176 ASTRAZENECA AB (SE) 2009-09-03 US disclosed
US-7053099-B1 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2006-05-30 US disclosed
EP-1235814-B1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2004-11-03 EP disclosed
US-4053470-A BACTERICIDES, ANTIBIOTICS PARKE, DAVIS & COMPANY (US) 1977-10-11 US disclosed